Patents by Inventor Michael D. Monroe

Michael D. Monroe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240122951
    Abstract: This invention is related to the field of PCSK9 biology and the composition and methods of use of small molecule ligands for modulation of PCSK9 biological activity. In particular, the invention provides compositions of small molecule compounds that modulate circulating levels of low density lipoproteins by altering the conformation of the protein PCSK9. Binding these small molecule ligands to PCSK9 alters the conformation of the protein, modifying the interaction between PCSK9 and an endogenous low density lipoprotein receptor, and can lead to reduced or increased levels of circulating LDL-cholesterol, High LDL-cholesterol levels are associated with increased risk for heart disease. Low LDL-cholesterol levels may be problematic in other conditions, such as liver dysfunction; thus, there is also utility for small molecule ligands that can raise LDL levels.
    Type: Application
    Filed: September 11, 2023
    Publication date: April 18, 2024
    Inventors: Thomas E Barta, Jonathan W. Bourne, Kyle D. Monroe, Michael M. Muehlemann
  • Patent number: 11945782
    Abstract: This invention is related to the field of PCSK9 biology and the composition and methods of use of small organic compounds as ligands for modulation of PCSK9 biological activity. In particular, the invention provides compositions of small organic compounds that modulate circulating levels of low density lipoproteins by altering the conformation of the protein PCSK9. Binding these small organic compound ligands to PCSK9 alters the conformation of the protein, modifying the interaction between PCSK9 and an endogenous low density lipoprotein receptor, and can lead to reduced or increased levels of circulating LDL-cholesterol. High LDL-cholesterol levels are associated with increased risk for heart disease. Low LDL-cholesterol levels may be problematic in other conditions, such as liver dysfunctions; thus, there is also utility for small organic compound ligands and can raise LDL levels.
    Type: Grant
    Filed: November 13, 2020
    Date of Patent: April 2, 2024
    Assignee: SRX Cardio, LLC
    Inventors: Thomas E. Barta, Jonathan William Bourne, Kyle D. Monroe, Michael M. Muehlemann, Anjali Pandey, Simeon Bowers
  • Patent number: 11944619
    Abstract: This invention is related to the field of PCSK9 biology and the composition and methods of use of small organic compounds as ligands for modulation of PCSK9 biological activity. In particular, the invention provides compositions of small organic compounds that modulate circulating levels of low density lipoproteins by altering the conformation of the protein PCSK9. Binding these small organic compound ligands to PCSK9 alters the conformation of the protein, modifying the interaction between PCSK9 and an endogenous low density lipoprotein receptor, and can lead to reduced or increased levels of circulating LDL-cholesterol. High LDL-cholesterol levels are associated with increased risk for heart disease. Low LDL-cholesterol levels may be problematic in other conditions, such as liver dysfunction; thus, there is also utility for small organic compound ligands that can raise LDL levels.
    Type: Grant
    Filed: September 14, 2020
    Date of Patent: April 2, 2024
    Assignee: SRX Cardio, LLC
    Inventors: Thomas E. Barta, Jonathan William Bourne, Kyle D. Monroe, Michael M. Muehlemann, Anjali Pandey, Simeon Bowers
  • Patent number: 11925637
    Abstract: This invention is related to the field of PCSK9 biology and the composition and methods of use of small organic compounds as ligands for modulation of PCSK9 biological activity. In particular, the invention provides compositions of small organic compounds that modulate circulating levels of low density lipoproteins by altering the conformation of the protein PCSK9. Binding these small organic compound ligands to PCSK9 alters the conformation of the protein, modifying the interaction between PCSK9 and an endogenous low density lipoprotein receptor, and can lead to reduced or increased levels of circulating LDL-cholesterol. High LDL-cholesterol levels are associated with increased risk for heart disease. Low LDL-cholesterol levels may be problematic in other conditions, such as liver dysfunction; thus, there is also utility for small organic compound ligands that can raise LDL levels.
    Type: Grant
    Filed: March 30, 2021
    Date of Patent: March 12, 2024
    Assignee: SRX Cardio, LLC
    Inventors: Thomas E. Barta, Jonathan William Bourne, Kyle D. Monroe, Michael M. Muehlemann, Anjali Pandey, Simeon Bowers
  • Patent number: 5884441
    Abstract: An art glass display formed primarily of a framework, at least one protective sheet of a translucent material adjacent the framework, and a peripheral border in contact with a portion of the framework and the translucent material. The framework is comprised of a plurality of cames and connectors in interconnected relationship. The cames are formed having a first sidewall portion, a second sidewall portion, and a pair of grooves extending the length of each came intermediate the first sidewall portion and the second sidewall portion, with the grooves being on opposite sides of the came. The connectors are formed having a center section, and a plurality of arms. The center section has a notch formed therein. The framework has retained therein at least one pane of glass, each pane of glass being approximately 3.1 mm (1/8") thick and having a bevelled edge.
    Type: Grant
    Filed: October 9, 1997
    Date of Patent: March 23, 1999
    Inventors: James L. Monroe, Jr., Michael D. Monroe, Jeffrey J. Menhart